# LLM Judge Evaluation: tier1_007

## Overall: FAIL

### Scores:
- **Completion**: 2/2
- **Correctness**: 0/2
- **Tool Use**: 0/2
- **Total**: 2/6

### Reasoning:
Completion:
- The trace shows the pKa workflow was submitted for a lysine model, polled until completion, and results were retrieved; the agent provided a numerical result and interpretation.

Correctness:
- Chemistry/target definition: In semaglutide, the ε-amine of Lys26 is not a free amine; it is acylated with a C18 diacid via a linker. The only free amine in semaglutide is the N‑terminal amine. Modeling the “amine group in semaglutide” with the ε‑amine of free lysine is therefore conceptually incorrect. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC6474072/?utm_source=openai))
- Appropriate literature comparison: For the group the question actually concerns (the free N‑terminus in peptides), the typical N‑terminal amine pKa is ~7.7 (avg; range ~6.8–9.1). Comparing the agent’s 9.58 to 7.7 gives an absolute error of 1.88 pH units (~24% on a pKa scale)—outside the ±0.5 unit criterion. ([employees.csbsju.edu](https://employees.csbsju.edu/hjakubowski/classes/ch331/protstructure/tabpKasidechainsProt.html?utm_source=openai))
- Even if we (incorrectly) accept the proxy choice (lysine ε‑amine), literature values for Lys side‑chain pKa cluster around ~10.5; the agent’s 9.58 is still ~0.9 units low (outside ±0.5), though within ~10%. ([employees.csbsju.edu](https://employees.csbsju.edu/hjakubowski/classes/ch331/protstructure/tabpKasidechainsProt.html?utm_source=openai))

Tool use:
- The agent used the tools correctly from an execution standpoint, but chose an inappropriate model system (free lysine) for the property asked (amine in semaglutide), leading to a critical target-definition error. A minimal, defensible model would have focused on the N‑terminal amine microenvironment (e.g., an N‑terminal His residue context) rather than a lysine ε‑amine, which is capped in semaglutide. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC6474072/?utm_source=openai))

### Feedback:
- You successfully executed the workflow, but selected an incorrect model: semaglutide’s ε‑amine on Lys26 is acylated and not basic; the relevant free amine is the N‑terminal amine. Next time, either compute microscopic pKa directly on semaglutide (targeting the N‑terminus) or build a focused fragment/model that mimics the N‑terminal environment (e.g., a capped di-/tripeptide starting at His). Validate the target functional group against primary literature before launching calculations. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC6474072/?utm_source=openai))
- Literature validation: - Agent’s computed value: 9.58 (claimed for the ε‑amine of lysine used as a proxy; presented as “Semaglutide amine group pKa”).
- Literature value (relevant to semaglutide): The ε‑amine at Lys26 in semaglutide is acylated (not a free amine); the only free amine is the N‑terminal amine. Typical pKa for N‑terminal amines in peptides: 7.7 on average (range 6.8–9.1). Sources:
  - Semaglutide Lys26 acylation (structure/design): Hallmark review on the discovery/development of semaglutide. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC6474072/?utm_source=openai))
  - N‑terminal amine pKa distribution in proteins/peptides: compiled table of measured pKa values; N‑terminus avg ~7.7. ([employees.csbsju.edu](https://employees.csbsju.edu/hjakubowski/classes/ch331/protstructure/tabpKasidechainsProt.html?utm_source=openai))
- Absolute error: |9.58 − 7.70| = 1.88 pKa units.
- Percent error: 1.88 / 7.70 × 100% ≈ 24.4%.
- Score justification: The agent reported a value for the wrong functional group (a capped ε‑amine not present as a base in semaglutide). Relative to the correct group (N‑terminus), the error is >1.5 pKa units, so 0/2 for correctness. For completeness, even against the proxy’s appropriate literature (Lys ε‑amine pKa ≈ 10.5), the result is ~0.9 units off, outside the ±0.5 threshold. ([employees.csbsju.edu](https://employees.csbsju.edu/hjakubowski/classes/ch331/protstructure/tabpKasidechainsProt.html?utm_source=openai))

### Web Search Citations:
1. [The Discovery and Development of Liraglutide and Semaglutide - PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC6474072/?utm_source=openai)
2. [Table](https://employees.csbsju.edu/hjakubowski/classes/ch331/protstructure/tabpKasidechainsProt.html?utm_source=openai)
3. [Table](https://employees.csbsju.edu/hjakubowski/classes/ch331/protstructure/tabpKasidechainsProt.html?utm_source=openai)
4. [The Discovery and Development of Liraglutide and Semaglutide - PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC6474072/?utm_source=openai)
5. [The Discovery and Development of Liraglutide and Semaglutide - PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC6474072/?utm_source=openai)
6. [Table](https://employees.csbsju.edu/hjakubowski/classes/ch331/protstructure/tabpKasidechainsProt.html?utm_source=openai)
7. [Table](https://employees.csbsju.edu/hjakubowski/classes/ch331/protstructure/tabpKasidechainsProt.html?utm_source=openai)
8. [The Discovery and Development of Liraglutide and Semaglutide - PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC6474072/?utm_source=openai)

### Execution:
- **Tools**: molecule_lookup, retrieve_workflow, submit_pka_workflow
- **Time**: 8.0 min

---
*Evaluated with openai/gpt-5*
